DSGN · Design Therapeutics, Inc.

Track DSGN — free

$10.34 +0.10 (+0.98%) At close · Oct 26

Russell 2000 member Rebalance outlook locked

Market Cap

$647.09M

62.58M

Volume · Oct 26 316.7K Avg daily vol (3M) 593.08K

Up next

Next earnings call

Feb 20, 2027 Est · unconfirmed · in 17 wks

Latest filing: 10-Q

filed Aug 3, 2026

Q3 2025 earnings call transcript

call held Nov 5, 2025

Metrics snapshot

Useful current figures from the complete screener profile.

View all 122 metrics

Revenue (TTM)

Trailing 12 months

Net income (TTM)

−$70.80M

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-8.5%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$207.40M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+9.9%

Year over year · more shares

Price change (1Y)

+80.5%

Trailing year

Short interest

10.6%

Latest settlement · 12.0 days to cover

View all 122 metrics

Quarterly results

Revenue Net income Net loss

· $142,000 −$663,000 '20 Q1 · $31,000 −$1.44M '20 Q2 · $20,000 −$2.32M '20 Q3 · $33,000 −$3.85M '20 Q4* · $0 −$17.71M '25 Q1 LATEST · $0 −$17.64M '26 Q1

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High

Market backdrop VIX 18.4 · elevated Equity put/call 0.60

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg −15%

below

Price vs 50-day avg −21%

below

RSI (14) 37

neutral

MACD trend Positive

52-week position 42%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return −16%

trailing

6-month return −23%

trailing

YTD return +10%

this year

Relative strength −29%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $13 › 200d $12 — 50d above 200d

Institutional flow Accumulating

17 of 136 funds reported for Sep 30 · net +8.8K sh shares · +1 new

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

10.63% of float · ▲ +0.6% MoM · 12.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

136 holders — near 3-yr high, broad support

Squeeze score 58

elevated · 0–100

Fundamentals

Weak

EPS growth −39%

Y/Y

Free cash flow $-54.6M

Balance sheet $16.9M

net cash

Quant / Vol

risk profile

Very High

Volatility 74%

annualized · 1-yr

Max drawdown −39%

past year

ATR 6.3%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

2 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−15% Bearish

Price vs 50-day avg

−21% Bearish

RSI (14)

37 Neutral

MACD trend

Positive Bullish

52-week position

42% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $13 › 200d $12 — 50d above 200d

Institutional flow Accumulating

17 of 136 funds reported for Sep 30 · net +8.8K sh shares · +1 new

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

10.63% of float · ▲ +0.6% MoM · 12.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

136 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $6 Now $10 · 42% Range high $16

vs 200-day avg -15% vs 50-day avg -21%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
DSGN Design Therapeutics, Inc. this stock	$647.09M	+10.2%	—	—	10.6%
VRTX Vertex Pharmaceuticals Inc	$130.00B	+14.1%	+46.2%	29.9	1.7%
REGN Regeneron Pharmaceuticals, Inc.	$82.88B	+4.6%	+20.8%	19.9	2.1%
MRNA Moderna, Inc.	$79.89B	+574.3%	+4.3%	—	8.2%
CSLLY Csl Ltd	$65.57B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

135

% held: 71.7%
Reported: 17 of 136
Top holder: SR One Capital Management…

Held Float

View

Held by Funds

Fund positions

155

View

Short & Settlement

Short Interest Rising

Shares short

6.7M

Days to cover: 12.0d
Change: +37.1K sh

View

Short Volume

Short vol %

55%

As of: Oct 26, 2026

Short Total

View

Fails to Deliver

FTD shares

884

Value: $11.2K
As of: Sep 30, 2026

View

Off-Exchange

Off-exchange %

34.2%

Week of: Sep 21, 2026

Off-exch Lit

View

Financials

Revenue (FY)

Net income (FY): $-69.8M
EPS diluted: $-1.22

View

Filings

SEC Filings

Latest

10-Q

Filed: Aug 3, 2026
This year: 15

View

Proposed Sales

Value

$891.6K

Shares: 120.0K
Filed: Nov 18, 2025

View

Exempt Offerings

Offering

$125.0M

Filed: Feb 12, 2021

View

Earnings & Events

Webcasts

Last webcast

Jun 4, 2026

View

Performance

	5D	20D	120D	MTD	YTD
DSGN	-2.8%	-16.3%	-22.9%	-17.7%	+10.2%
SPY	-0.1%	0.0%	+5.8%	+0.4%	+12.2%
vs SPY	-2.7%	-16.3%	-28.6%	-18.1%	-2.0%

Key facts CIK 1807120 CUSIP 25056L103 13F (30d) 16 filings 16 filers Visit website Investor relations

DSGN · Design Therapeutics, Inc.

Price & Indicators

Up next

Metrics snapshot

Quarterly results

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance